Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Capital Leases (2016)

Arrowhead Pharmaceuticals' Capital Leases history spans 6 years, with the latest figure at $378862.0 for Q2 2016.

  • For Q2 2016, Capital Leases fell 36.38% year-over-year to $378862.0; the TTM value through Jun 2016 reached $378862.0, down 36.38%, while the annual FY2015 figure was $540792.0, 28.69% down from the prior year.
  • Capital Leases reached $378862.0 in Q2 2016 per ARWR's latest filing, down from $430665.0 in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $1.4 million in Q1 2012 to a low of $378862.0 in Q2 2016.
  • Average Capital Leases over 5 years is $878776.7, with a median of $838973.0 recorded in 2014.
  • Peak YoY movement for Capital Leases: decreased 15.0% in 2012, then tumbled 36.38% in 2016.
  • A 5-year view of Capital Leases shows it stood at $1.2 million in 2012, then dropped by 18.03% to $1.0 million in 2013, then dropped by 29.93% to $705173.0 in 2014, then plummeted by 31.1% to $485842.0 in 2015, then fell by 22.02% to $378862.0 in 2016.
  • Per Business Quant, the three most recent readings for ARWR's Capital Leases are $378862.0 (Q2 2016), $430665.0 (Q1 2016), and $485842.0 (Q4 2015).